课题基金 / 基金详情

Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma

Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
批准号:
10435036
负责人:
OFER LEVY
金额:
$12.39万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-03-10 至 2027-02-28

项目摘要

项目成果

OFER LEVY的其他基金

相似基金

相关文献

中文摘要
翻译
项目概要:IDEAL行政核心 我们的总体建议将调查免疫发育的早期生活(理想),以确定理想的内涵型 这与儿童期的关键临床结果相对应,包括疫苗反应,呼吸道感染, 疾病和哮喘。我们将通过以下三个不同但综合的研究来实现这一目标 通过计算机模拟(项目1,PR 1)、表观遗传学(PR 2)和体外(PR 3)的尖端互补方法 研究项目。鉴于拟议工作的科学范围、复杂性和地理范围, 研究IDEAL行政核心(AC)将是至关重要的,以优化拟议的质量和影响, 研究,并确保及时提供预计的交付成果。IDEAL-AC的目标是 简化的流程,促进每个IDEAL项目的研究人员之间富有成效的互动 和核心。我们将通过以下具体目标实现这一目标: SA 1.为行政领导提供基础设施, 协作的工作团队,最大限度地发挥项目的协同作用。 SA 2.促进项目和核心领导之间的沟通和互动 通过定期举行电话会议/面对面会议、年度会议以及 以IDEAL项目为重点的研讨会/专题讨论会。 SA 3.管理和优化IDEAL团队内部以及我们的团队、 其他NIH支持IDEAL团队和IDEAL指导委员会。 SA 4.解决IDEAL项目内外可能出现的潜在冲突, 执行冲突解决小组的建议。 SA 5.提供财政、监管和科学监督,审查和巩固年度进展 将报告发送给NIH。 SA6.保护我们研究人员的知识产权并执行材料转移 协定 SA7。在我们内部和外部的研究者之间实施数据管理/共享计划 理想的团队 总体而言,IDEAL AC将确保NIH资金的适当管理,并保持遵守 项目时间表,所有这些都是为了优化和扩大拟议研究的科学影响。
英文摘要
PROJECT SUMMARY: IDEAL Administrative Core Our overall proposal will investigate immune development in early life (IDEAL) to identify IDEAL endotypes that correspond to key clinical outcomes in childhood, including vaccine response, respiratory infectious disease and asthma. We will accomplish this goal through three distinct yet integrated studies that follow complementary approaches via cutting-edge in silico (project 1, PR1), epigenetic (PR2), and in vitro (PR3) research projects. Given the scientific scope, complexity, and geographic range of the proposed work, the study IDEAL Administrative Core (AC) will be crucial to optimize the quality and impact of the proposed studies and to ensure timely provision of projected deliverables. The goal of the IDEAL-AC is to institute streamlined processes which facilitate productive interactions among investigators from each IDEAL Project and Core. We will achieve this goal by pursuing the following Specific Aims (SAs): SA1. Provide infrastructure for administrative leadership aimed at building an interactive and collaborative working team resulting in maximal project synergy. SA2. Facilitate and promote communication and interactions amongst the Project and Core Leads by conducting regular teleconferences/face-to-face meetings, annual meetings, as well as seminars/symposia focused on the IDEAL project. SA3. Manage and optimize communication within our IDEAL team and between our team, the other NIH supported IDEAL teams and the IDEAL Steering Committee. SA4. Resolve potential conflicts that might arise within and outside of our IDEAL project by implementing recommendations of the Conflicts Resolution Group (CRG). SA5. Provide fiscal, regulatory and scientific oversight, review and consolidate yearly progress reports sent to the NIH. SA6. Protect intellectual property rights of our investigators and execute material transfer agreements. SA7. Implement the data management/sharing plan among investigators within and outside of our IDEAL team. Overall, the IDEAL AC will ensure appropriate stewardship of NIH funds and maintain adherence to project timelines, all with the goal to optimize and amplify the scientific impact of the proposed studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
  • 批准号:
    10435035
  • 项目类别:
  • 资助金额:
    $166.59万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
  • 批准号:
    10589826
  • 项目类别:
  • 资助金额:
    $22.79万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
  • 批准号:
    10435043
  • 项目类别:
  • 资助金额:
    $19.86万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
  • 批准号:
    10589800
  • 项目类别:
  • 资助金额:
    $154.65万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
海外基金